30th week of 2022 patent applcation highlights part 24 |
Patent application number | Title | Published |
20220235054 | NOVEL MALEATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVES, COMPOSITIONS, METHODS OF USE, AND PROCESSES OF MANUFACTURING THE SAME - Pharmaceutical compositions and methods of using maleate salts of triazolopyrazine derivatives are provided. In some aspects, the pharmaceutical compositions have improved storage stability and pharmacokinetic properties. The maleate salts of triazolopyrazine derivatives bind competitively to the phosphorylation site of c-MET kinase and can be used for the treatment or prevention of various hyper proliferative disorders. | 2022-07-28 |
20220235055 | 5-(2,5-DIFLUOROPHENYL)PYRROLIDIN-1-YL)-3-(1H-PYRAZOL-1-YL)PYRAZOLO [1,5-A]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATING CANCER - The application relates to inhibitors of Trk kinases useful in the treatment of Trk kinase associated diseases and disorders, having the Formula: | 2022-07-28 |
20220235056 | ADENOSINE 2 RECEPTOR ANTAGONISTS - The instant disclosure provides novel adenosine receptor antagonist compounds, compositions, methods of making and methods of using. In a further aspect, a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of any one or more of the compounds described herein. In some embodiments, the subject has cancer and the method is a method of treating cancer. | 2022-07-28 |
20220235057 | CYCLIC FORMYL AND CYCLIC KETONE COMPOUNDS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE - The present invention provides a cycloyl formyl and cycloyl ketone compounds, a preparation method therefor, and a pharmaceutical use. The present invention finds that the compounds shown in formula (I) better inhibits Zika virus and dengue virus infection and replication, may be used as a drug for treating and preventing diseases caused by Zika virus and dengue virus, and may also become a drug for treating and preventing diseases caused by other flaviviruses, such as yellow fever, West Nile virus infection, Japanese encephalitis, AIDS caused by HIV etc., and diseases caused by hand, foot and mouth virus infection etc. The compounds may treat disease caused by bacterial infections, including inflammatory bowel disease ulcerative colitis and Crohn's disease, diseases caused by | 2022-07-28 |
20220235058 | PROCESSES AND INTERMEDIATES FOR PREPARING A BTK INHIBITOR - Disclosed is a process for the preparation of certain intermediates, e.g. process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, in an enantioenriched form, which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib. | 2022-07-28 |
20220235059 | ANTIBACTERIAL COMPOUNDS - The present invention relates to compounds of formula (I) their salts and derivatives. Further object of the present invention are compositions, which comprise at least one compound of formula (I) or its pharmaceutically acceptable salts and derivatives and excipients and, optionally, a further active compound. Further object of the present invention are compounds of formula (I) or compositions which comprise them for use as antibacterial agents. | 2022-07-28 |
20220235060 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS - The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X | 2022-07-28 |
20220235061 | TRIAZOLOPYRIMIDINE COMPOUND AND SALT, COMPOSITION AND USE THEREOF - The present disclosure relates to triazolopyrimidine compounds and salts, compositions and uses thereof, and the triazolopyrimidine compounds have the structures represented by the formula (I): | 2022-07-28 |
20220235062 | P2X7 MODULATORS - The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: | 2022-07-28 |
20220235063 | MORPHIC FORMS OF MARIZOMIB AND USES THEREOF - The present invention relates to polymorphic forms of marizomib (e.g., Morphic Form I). The morphic forms can be used alone and in pharmaceutical compositions for the treatment of disease. | 2022-07-28 |
20220235064 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - An oxo-pyridine fusion ring compound of chemical formula 1 or a pharmaceutically acceptable salt thereof effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines. Therefore, the oxo-pyridine fusion ring compound of chemical formula 1 or a pharmaceutically acceptable salt thereof can be advantageously used for preventing or treating a disease associated with protein kinase activity: | 2022-07-28 |
20220235065 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF - The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted heterocyclic heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes. | 2022-07-28 |
20220235066 | OXABICYCLOHEPTANE PRODRUGS - The present invention provides a compound having the structure: | 2022-07-28 |
20220235067 | COMPOSITIONS AND METHODS OF FABRICATION OF NEAR INFRARED DEVICES - A composition of matter including a donor including a dithiophene unit combined with a non-fullerene acceptor. Further disclosed is a device comprising an active region including the composition of matter. Example devices include a solar cell or a photodetector. | 2022-07-28 |
20220235068 | TETRACYCLIC COMPOUNDS AS CDC7 INHIBITORS - A new class of tetracyclic compounds acting as Cdc7 inhibitors; specifically disclosed are a compound represented by formula (I), isomers thereof, or pharmaceutically acceptable salts thereof. | 2022-07-28 |
20220235069 | MTORC1 MODULATORS AND USES THEREOF - The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease. | 2022-07-28 |
20220235070 | MACROLIDE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF - Provided are a macrolide derivative represented by formula (I), a preparation method thereof, and an application of the macrolide derivative as an inhibitor of one or more protein kinases of TRK, ALK and ROS1, | 2022-07-28 |
20220235071 | LUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR LUMINESCENCE DEVICE - Provided is a luminescence device including a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region, wherein the hole transport region may include a polycyclic compound represented by Formula 1, thereby exhibiting a long service life and high efficiency. | 2022-07-28 |
20220235072 | SEMI-SYNTHETIC ANALOGUES OF EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS - Disclosed herein are compounds, compositions, and methods for inhibiting a histone methyltransferase. The compounds are verticillin derivatives that exhibit anti-proliferative activity against cancer cells. The compounds, compositions, and methods can be used to treat a subject with cancer. | 2022-07-28 |
20220235073 | ARTEMISININ-DERIVATIVE N-HETEROCYCLIC CARBENE GOLD(I) HYBRID COMPLEXES - The present invention relates to compounds of formula (I), which are artemisinin-derivative N-heterocyclic carbene gold (1) hybrid complexes, and to their therapeutic uses. | 2022-07-28 |
20220235074 | METHOD FOR FORMING A METAL-ORGANIC FRAMEWORK - A method for forming a metal-organic framework comprising a step of providing a substrate; a single step of forming a single layer of metal oxide formed on the substrate said layer of metal oxide being transformed in whole or in part into metal-organic framework by successive implementation of a plurality of reaction cycles; each reaction cycle of the plurality of reaction cycles comprising: a treatment step with at least one ligand; a treatment step with at least one additive; the reaction cycles being implemented at least twice so as to form the metal-organic framework on the substrate. | 2022-07-28 |
20220235075 | VOLTAGE SENSITIVE DYES - Voltage sensitive dyes comprising boron and related compositions and methods are provided. In some embodiments, a voltage sensitive dye comprises an electron acceptor comprising boron. The electron acceptor may be attached (e.g., covalently) to at least one electron donating group and at least one polar group. For instance, the electron acceptor may comprise optionally substituted boron dipyrromethene (e.g., optionally substituted 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene). The point of attachment and chemical nature of the electron donating group(s) and polar group(s) may be selected to impart beneficial properties to the voltage sensitive dye. For instance, the voltage sensitive dye may have an extended difference in the dipole moment between the ground and electronic states due at least in part to the position of the electron donating group(s). The voltage sensitive dyes, described herein, may have high specificity, high signal to noise ratio, fast responsivity, high voltage sensitivity, high photostability, and/or high brightness. | 2022-07-28 |
20220235076 | METHODS FOR MAKING LOW BANDGAP PEROVSKITES - The present disclosure relates to a composition that includes a perovskite having a stoichiometry comprising A | 2022-07-28 |
20220235077 | PHOSPHINE PRECURSOR FOR PREPARING QUANTUM DOT AND QUANTUM DOT PREPARED THEREFROM - The present invention relates to a phosphine precursor for the preparation of a quantum dot, and a quantum dot prepared therefrom. Using the phosphine precursor for the preparation of a quantum dot of the present invention, a quantum dot with improved luminous efficiency and higher luminous color purity can be provided. | 2022-07-28 |
20220235078 | COT MODULATORS AND METHODS OF USE THEREOF - The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof. | 2022-07-28 |
20220235079 | Crystalline Forms of Tenofovir Alafenamide - The present invention provides novel crystalline forms of tenofovir alafenamide comprising tenofovir alafenamide and two different pharmaceutically acceptable acids, compositions and processes for the preparation thereof, and their use in the treatment of a human immunodeficiency virus (HIV) infection or a hepatitis B virus (HBV) infection. | 2022-07-28 |
20220235080 | SELECTIVE DETECTION OF BED BUGS - A device, system, and method of controlling pests are disclosed. A pest control device includes a sensor having a sensor cell and a controller. A surface of the sensor cell is coated with an agent that reacts with a targeted biochemical analyte secreted by pests. The controller is coupled to the sensor and is configured to receive sensor data from the sensor cell indicative of a rate of change in sensor mass detected on the surface of the sensor cell, determine whether the rate of change in the sensor mass based on the received sensor data exceeds a predefined threshold rate, and transmit a pest detection alert notification to a server in response to a determination that the rate of change exceeds the predetermined threshold rate. | 2022-07-28 |
20220235081 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE - An organometallic compound represented by Formula 1: | 2022-07-28 |
20220235082 | CATALYSTS - A compound, e g a diamine ligand, represented by the following general formula (1): (Formula (1)) wherein each * represents an asymmetric carbon atom; X represents a group selected from one of an ester (e.g. a t-butyl ester); a thioester; an amide; a heterocyclic moiety (e.g. a five-membered heterocyclic ring) comprising one or more of O, S, Se, and/or P (e.g. a furan, a tetrahydrofuran, a thiophene, an isoxazole, a bromo-furan, or a thiazole); a moiety (e.g. a five-membered heterocyclic ring) comprising a nitrogen atom, wherein the nitrogen atom is protected with a protecting group containing an electron-withdrawing group, preferably the protecting group is selected from one of a carbamate protecting group, an amide protecting group, an aryl sulphonamide protecting group, or an alkyl sulphonamide protecting group; and optionally X may additionally comprise a solid support, e.g. a polymeric or a silica particle; Y represents or is CtT′T″ where ‘t’ is 0 or 1 and when ‘t’ is 1 T′ and T″ may individually represent a substituent, e.g. if t is 1, T′ and/or T″ may each be hydrogen or deuterium atom, or a halogen atom; for example, Y may represent a carbon atom comprising two further substituents; Z represents a hydrogen atom or a deuterium atom; R | 2022-07-28 |
20220235083 | METHODS FOR THE PRODUCTION OF CALCIUM, MAGNESIUM, AND ZINC SALTS OF SUGAR ACIDS - A method has now been found for the preparation of calcium, magnesium, and zinc salts of sugar acids, this being the object of the present invention, which is characterized in that the method may include providing a sugar and oxidizing the sugar to a sugar acid in the presence of a noble metal catalyst, oxygen, and a heterogeneous hydroxide source. Preferably the oxidation is carried out with a gold catalyst, and a heterogeneous source of magnesium, calcium, or zinc hydroxide. The oxidation can be performed in a batch or continuous manner. | 2022-07-28 |
20220235084 | PRODUCTION OF OLIGOSACCHARIDES FROM POLYSACCHARIDES - Synthetic oligosaccharides and mixtures thereof which resemble polysaccharides produced by plants, yeast and other fungi, bacteria, and algae are described. The oligosaccharides and compositions provided herein are useful as synbiotics, prebiotics, immune modulators, digestion aids, and food additives. | 2022-07-28 |
20220235085 | PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF SOTAGLIFLOZIN - The present document relates to a process for the preparation of the crystalline form II of sotagliflozin, wherein said crystalline form II of sotagliflozin is directly obtained from the following compound of formula (A) and by using toluene or xylene or mixture thereof as solvent medium for the crystallization. | 2022-07-28 |
20220235086 | ASCAROSIDE DERIVATIVES AND METHODS OF USE - The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administering a composition comprising a compound having the structure of Formula (I). | 2022-07-28 |
20220235087 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE - The present invention relates to mannoside derivative compounds useful as inhibitors of FimH and methods for the treatment or prevention of urinary tract infection. | 2022-07-28 |
20220235088 | INHIBITORS OF ADENYLATE-FORMING ENZYME MENE - Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts or tautomers thereof which may inhibit adenylate-forming enzymes. Also provided are pharmaceutical compositions, kits, uses, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g., tuberculosis, methicillin-resistant | 2022-07-28 |
20220235089 | Multi-Fluorous Blockmer for Oligonucleotide Synthesis, and Oligonucleotide Synthesis Method Using the Same - Provided are a multi-fluorous blockmer using a readily available fluorous tag and capable of reducing burdens of purification, and an oligonucleotide synthesis method using the same. A multi-fluorous blockmer represented by the formula is synthesized: wherein B is a natural or modified nucleobase; R | 2022-07-28 |
20220235090 | OLIGONUCLEOTIDE MANUFACTURING METHOD - The present invention aims to provide a more stable and efficient method for producing oligonucleotide, particularly, oligonucleotide having various functional groups linked to the 3′-terminal and the like. Efficient production of oligonucleotide becomes possible by a production method of an oligonucleotide represented by the formula (Ia-2) (each symbol is as defined in the DESCRIPTION) and having a functional group at the 3′-terminal, the method including a step of subjecting an oligonucleic acid with 3′-terminal protected by a silyl-protecting group to 3′-terminal-selective deprotection under desilylation conditions that do not affect protecting groups other than the silyl group, subjecting same to phosphitylation conditions with a phosphoramidite reagent that do not affect protecting groups on the oligonucleic acid to give a 3′-terminal-phosphoramidited oligonucleotide represented by the formula (Ia-1) (each symbol is as defined in the DESCRIPTION), and linking a functional group to the 3′-terminal of the 3′-terminal phosphoramidited oligonucleotide directly or via a linker, and the like. | 2022-07-28 |
20220235091 | NUCLEIC ACID CONTAINING PERFLUOROALKYL GROUP, AND METHOD FOR ITS PRODUCTION - To provide a nucleic acid excellent in cell membrane permeability and a method for its production. | 2022-07-28 |
20220235092 | PROGESTERONE ANALOGS AND USES RELATED THERETO - This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke. | 2022-07-28 |
20220235093 | BILE SALT HYDROLASE PROBE AND METHOD OF MAKING AND USING THE SAME - Probe embodiments for targeting, identifying, and isolating enzymes exhibiting BSH activity as well as devices and kits that use the probes are described herein. Methods of making and using the probes, devices, and kits are also described. In some embodiments, probes, devices, and kits for targeting, identifying, and isolating enzymes in a biological sample are disclosed. In some embodiments, compositions and methods of treatment using the probes, devices, and kits disclosed herein are described. | 2022-07-28 |
20220235094 | CRYSTALLINE FORMS OF ANTIDEPRESSANT DRUG SAGE-217 AND PREPARATION METHOD THEREFOR - The present application relates to crystalline form 04, crystalline form 06, crystalline form D-1, and crystalline form D-2 of an antidepressant drug SAGE-217 and a preparation method therefor and a pharmaceutical composition containing same. The crystalline form 04 has an XRPD pattern with characteristic peaks at 2theta values of 11.6±0.2°, 13.5±0.2°, 16.2±0.2°, 16.5±0.2°, and 23.2±0.2°; the crystalline form 06 has an XRPD pattern with characteristic peaks at 2theta values of 8.7±0.2°, 10.0±0.2°, 13.2±0.2°, 15.0±0.2°, 15.8±0.2°, and 17.3±0.2°; the crystalline form D-1 has an XRPD pattern with characteristic peaks at 2theta values of 7.2±0.2°, 8.6±0.2°, 13.3±0.2°, 19.6±0.2°, and 23.0±0.2°; and the crystalline form D-2 has an XRPD pattern with characteristic peaks at 2theta values of 7.3±0.2°, 8.6±0.2°, 13.4±0.2°, 19.7±0.2°, and 23.3±0.2°. The novel crystalline forms provided by the present application have good stability, and provide more choices for drug development. | 2022-07-28 |
20220235095 | SAPONIN PURIFICATION - Saponin extracts containing at least 88% QS-21 main peak and >3% to 10% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects. | 2022-07-28 |
20220235096 | An improved process for the preparation of Plecanatide - The present invention relates to a process for the preparation of Plecanatide, which comprises preparation of three fragments such as Fragment A (7 amino acids), Fragment B (3 amino acids), Fragment D (6 amino acids) and coupling the fragments to provide Plecanatide followed by purification using buffer system comprising Tris hydrochloride (or) Triethylammonium phosphate. | 2022-07-28 |
20220235097 | METHODS OF TREATMENT AND RELATED COMPOSITIONS - The present invention relates to methods of treating a disease characterised by aberrant cell proliferation (e.g., a cancer) in a human subject in need thereof. In particular, the present invention relates to treating the above conditions by administering a therapeutically effective amount of at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon, and administering to the subject at least one agent that inhibits the Hedgehog (Hh) signalling pathway (e.g., Vismodegib). Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions, containing at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon (e.g., a checkpoint inhibitor), an inhibitor of Hh signalling pathway, and a controlled release matrix such as a SiO | 2022-07-28 |
20220235098 | MICROCIN MCCY, AND PREPARATION METHOD AND USE THEREOF - The present disclosure discloses a Microcin MccY, and a preparation method and use thereof, wherein the amino acid sequence of the Microcin MccY is GGRGHIAEYFSGPITQVSFYG. Compared with Microcin MccJ25 that only has a bactericidal activity against a small part of serotypes of | 2022-07-28 |
20220235099 | Structural Protein Microbody and Method for Producing Same, Method for Producing Nanofiber, and Method for Producing Protein Structure - Provided is a structural protein microbody that functions as a core for forming a protein nanofiber. There is provided a structural protein microbody including a structural protein, in which the structural protein microbody satisfies at least two of the following (i) to (iii): (i) a peak is present within a range of 480 to 500 nm in a fluorescence intensity measurement by thioflavin T staining; (ii) a peak is present in a region where Q is 0.15 or less in a modified Kratky plot of small angle X-ray scattering (SAXS); and (iii) the structural protein microbody is an aggregate of two or more structural protein molecules. | 2022-07-28 |
20220235100 | Water-Absorbing and Quick-Drying Property-Imparting Agent, and Method for Imparting Water-Absorbing and Quick-Drying Properties - Provided is a water-absorbing and quick-drying property-imparting agent capable of easily imparting water-absorbing and quick-drying properties to various materials or articles in a simple process, and a method capable of easily imparting water-absorbing and quick-drying properties to predetermined materials or articles. | 2022-07-28 |
20220235101 | Compositions and Methods for Regulation of Chronic Toxoplasma Infection - The present disclosure provides genetically altered protozoan parasites comprising a mutation in a bradyzoite formation deficient 1 (BFD1) gene, wherein the mutation inhibits differentiation of the parasite into a bradyzoite. The genetically altered protozoan parasites can be utilized in vaccine compositions and in methods of treating apicomplexan parasite infection. | 2022-07-28 |
20220235102 | SPECIFIC NUCLEAR-ANCHORED INDEPENDENT LABELING SYSTEM - Materials and methods for labeling and isolating particular cell types from mixed cell populations are provided herein. Also provided herein are methods for generating data representing a synthetic genetic sequence configured for labeling at least one cell type by causing expression of a marker in the at least one cell type. | 2022-07-28 |
20220235103 | NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USES - The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2. | 2022-07-28 |
20220235104 | NOVEL METHOD TO ENGINEER TRANSLANTABLE HUMAN TISSUES - This disclosure relates to methods, polynucleotides, vectors, viral particles, cells, and systems or the engineering of human tissues. One aspect of the disclosure relates to using lineage-specific miRNA binding molecules to bias tissue lineage. Another aspect of the disclosure relates to using lineage-specific transcription factor overexpression to bias tissue lineage. | 2022-07-28 |
20220235105 | METHODS AND COMPOSITIONS FOR VISUALIZING SUMO - The present disclosure describes pan-SUMO trapping proteins and fusion proteins comprising the pan-SUMO trapping proteins that are stable and bind SUMO-modified proteins with high avidity. The proteins described herein can be used to detect the localization of SUMO-modified proteins cells. The proteins described herein can be used to identify biomarkers for diseases associated with oxidative stress. They can also be used to diagnose and monitor diseases associated with genotoxic and/or proteotoxic stress conditions. | 2022-07-28 |
20220235106 | METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG - The present invention relates to a method for expressing, water-solubilizing, and purifying protein by using a calsequestrin-tag (CSQ-tag). Provided are: a recombinant expression vector containing a CSQ-tag and a target protein; a host cell transformed using the recombinant expression vector; and a method for expressing and purifying a target protein by using a CSQ tag. The present invention uses CSQ-tags to increase the expression of proteins that are widely used in pharmaceuticals and cosmetics, and allows the proteins to be easily separated by calcium, and thus is expected to be able to lower the cost of protein materials and protein pharmaceuticals. | 2022-07-28 |
20220235107 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-07-28 |
20220235108 | Methods and Compositions Based on Diphtheria Toxin-Interleukin-3 Conjugates - The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells. In other embodiments, the methods of the present invention relate to ex vivo purging of bone marrow or peripheral blood to remove cells that express one or more subunits of the interleukin-3 receptor such that the purged bone marrow or peripheral blood is suitable, e.g., for autologous stem cell transplantation to restore hematopoietic function. | 2022-07-28 |
20220235109 | NOVEL INTERLEUKIN-2 VARIANTS FOR THE TREATMENT OF CANCER - The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. A panel of IL-2 variants comprise mutations substantially reduce the ability of these polypeptides to stimulate Treg cells and make them more effective in the therapy of tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines, or TAA-targeting biologics, or immune checkpoint blocker, or as the building block in bifunctional molecule construct, for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is undesirable. In another aspect the present invention relates to pharmaceutical compositions comprising the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their selective modulating effect of the immune system on diseases like autoimmune and inflammatory disorders, cancer, and various infectious diseases. | 2022-07-28 |
20220235110 | De Novo Design of Potent and Selective Interleukin Mimetics - De novo designed polypeptides that bind to IL-2 receptor β | 2022-07-28 |
20220235111 | Variant Single-Chain Insulin Analogues - A single-chain insulin analogue containing (i) diverse amino-acid substitutions at position A14; (ii) wild-type or variant residues at positions A8 and A14; and (ii) an engineered C-domain segment of lengths 4-6 containing a specific set of Alanine substitutions and/or deletions derived from the prototype C-domain sequence Glu-Glu-Gly-Pro-Arg-Arg. The analogue may otherwise be an analogue of a mammalian insulin, such as human insulin, may optionally include standard or non-standard modifications that (i) augment the stability of insulin, (ii) cause a shift in the isoelectric point to enhance or impair the solubility of the protein at neutral pH or (iii) reduce cross-binding of the protein to the Type I IGF receptor. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions under acidic or neutral pH values (e.g., pH 3.0-4.2 and 6.5-7.8, respectively) and optionally in the presence of zinc ions at a molar ratio of 2.2-10 zinc ions per six insulin analogue monomers. A method of treating a patient with diabetes mellitus comprising the administration of a physiologically effective amount of the protein or a physiologically acceptable salt thereof to a patient. Use of a single-chain insulin analogue of the present invention in an insulin delivery device (such as a pump or pen) is envisioned. | 2022-07-28 |
20220235112 | GBD-SSTAD-SSTAD RECOMBINANT PROTEIN AND METHOD FOR PRODUCING AND USING SAME - The present invention relates to genetic engineering, biotechnology, immunology, and microbiology. Recombinant GBD-SSTad-SSTad protein and a method for preparation thereof on glucan are described, including the binding of GBD-SSTad-SSTad protein in cell extracts of | 2022-07-28 |
20220235113 | TCR Libraries - The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs may consist essentially of TCRs which may comprise an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable domain may comprise a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain may comprise a TRBV6 gene product. | 2022-07-28 |
20220235114 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS - Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a co-stimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 that enhances CAR-T cell function, e.g. by reducing CAR-T cell exhaustion. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. | 2022-07-28 |
20220235115 | Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof - Novel synthetic biology-based ADCC technologies are provided that enhance or enable ADCC responses, for example, through a rationally-designed soluble universal ADCC enhancer protein (SUAEP) where a high-affinity CD3-binding domain is fused to a high-affinity Fc-binding domain. The SUAEP technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable. | 2022-07-28 |
20220235116 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME - The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions. | 2022-07-28 |
20220235117 | NOVEL ANTI-HEPATITIS B VIRUS ANTIBODY AND USES THEREOF - Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV. | 2022-07-28 |
20220235118 | ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEIN - Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies. | 2022-07-28 |
20220235119 | COMPOSITIONS AND METHODS FOR TREATING A COVID-19 INFECTION - Provided herein are methods of treating a COVID-19 infection in a subject, comprising administering to the subject an effective amount of a composition that reduces the superantigen character of SARS-CoV-2 Spike protein. In some embodiments, the compositions are mimetic peptides of the superantigen region. In some embodiments, the compositions are humanized antibodies, such as humanized mAb 6D3, that bind to the superantigen region. | 2022-07-28 |
20220235120 | HUMANIZED TETRA-SPECIFIC OCTAVALENT ANTIBODY AGAINST CLOSTRIDIUM DIFFICILE TOXIN A AND B - Novel, antibody-based binding agents derived from camelid V | 2022-07-28 |
20220235121 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) - Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof. | 2022-07-28 |
20220235122 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - The invention is directed to a short term induction treatment with anti-N3pGlu Aβ antibodies of a disease characterized by deposition of Aβ in the brain, that include Alzheimer's disease (Aβ), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aβ antibody for a period of 6 months or less. | 2022-07-28 |
20220235123 | SYNTHETIC ANTIBODIES AGAINST VEGF AND THEIR USES - The invention provides novel synthetic antibodies directed against VEGF and uses thereof. | 2022-07-28 |
20220235124 | ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL) - Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy. | 2022-07-28 |
20220235125 | Method of Treating Dupuytren's Disease Using A Pre-filled Syringe - The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method. | 2022-07-28 |
20220235126 | NOVEL ANTIGEN BINDING MOLECULE FORMATS - Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs. | 2022-07-28 |
20220235127 | ANTI-NOTCH3 ANTIBODY - Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3. | 2022-07-28 |
20220235128 | ANTI-CLDN ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND DETECTION METHOD THEREFOR - Provided are an anti-CLDN18.2 antibody and a pharmaceutical composition thereof and a detection method therefor, wherein the heavy chain of the antibody is selected from any one of SEQ ID NOs: 1-7 or SEQ ID NOs: 15-30, and the light chain of the antibody is selected from any one of SEQ ID NOs: 8-14 or SEQ ID NOs: 31-46. The ability of the antibody to bind to cell lines and tumor tissue cells is more powerful than that of the existing antibody IMAB362, and the anti-tumor effect of the antibody is also more powerful than that of the existing antibody IMAB362. | 2022-07-28 |
20220235129 | CLDN18.2 ANTIBODY AND USE THEREOF - Provided are a CLDN18.2-combined antibody and an unfucosylated form thereof. Further provided are a preparation method for the antibody, a conjugate, and a composition containing the antibody, and use thereof in the treatment of a disease such as cancer. | 2022-07-28 |
20220235130 | Anti-TIM3 monoclonal antibodies and chimeric antigen receptors - Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment. | 2022-07-28 |
20220235131 | METHODS OF TREATING INFECTIONS BY BLOCKING PATHOGEN MIMICS OF CD47 - Methods are provided for treating a subject for an infection by a pathogen expressing a CD47-like mimic protein on its surface. In particular, the methods comprise administering an agent that reduces the binding of the CD47 mimic protein on the pathogen to SIRPα on a phagocytic cell, wherein the agent is administered at an effective dose for increasing phagocytosis of the pathogen | 2022-07-28 |
20220235132 | PD-1 AGONIST AND METHOD OF USING SAME - Provided is a PD-1-binding agent comprising an immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide, as well as related compositions and methods for making and using same. | 2022-07-28 |
20220235133 | MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN DIMER AND APPLICATION THEREOF - Provided are a monoclonal antibody-cytokine fusion protein dimer and an application thereof. The monoclonal antibody comprises two heavy chains, the fusion protein dimer comprises a first heavy chain polypeptide chain and a second heavy chain polypeptide chain, wherein one heavy chain of the monoclonal antibody is connected to a cytokine to form the first heavy chain polypeptide chain, and the other heavy chain of the monoclonal antibody is optionally connected to another cytokine to form the second heavy chain polypeptide chain. The monoclonal antibody-cytokine fusion protein dimer provided not only fully retains the biological activity of the antibody, but also significantly improves the biological activity of the cytokine(s). More importantly, by using the target specificity of the antibody molecule, the immune response of immune cells is enhanced and the toxicity of the cytokine(s) is reduced, and thus, on the premise of enhancing the efficacy of the drug, the safety of the medication is ensured. | 2022-07-28 |
20220235134 | ANTI-B7-H3 ANTIBODIES - Provided are antibodies that specifically recognize B7 homology 3 protein (B7-H3). | 2022-07-28 |
20220235135 | ACTIVATING ANTI-GAL9 BINDING MOLECULES - Anti-GAL9 antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented. | 2022-07-28 |
20220235136 | METHODS AND COMPOSITIONS FOR TREATING A DISEASE OR DISORDER - The present application provides agents that specifically inhibits the IGFBP7/CD93 signaling pathway, such as agents that specifically block the interaction between CD93 and IGFBF7, methods of using said agents and methods of identifying said agents. | 2022-07-28 |
20220235137 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE - Antibodies and compositions against IGF-1R and uses thereof are provided herein. | 2022-07-28 |
20220235138 | CAR-T CELLS TARGETING IL-1RAP AND THEIR USE IN ACUTE MYELOID LEUKEMIA (AML) - The present invention is relative to a cell comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR) for use in the treatment of acute myeloid leukemia (AML), wherein the CAR comprises an antibody or antibody fragment which includes an anti-IL-1RAP binding domain, a transmembrane domain, and an intracellular signaling domain comprising at least a stimulatory domain | 2022-07-28 |
20220235139 | ANTI-CSF-IR ANTIBODY - The present invention relates to a monoclonal antibody, or fragment thereof, which binds to CSF-1R (Colony stimulating factor 1 receptor), in particular to human CSF-1R. The present invention further relates to the in vitro use of the monoclonal antibody, or fragment thereof, of the present invention for the detection of CSF-1R in a sample. Further encompassed by the present invention is a complex comprising the monoclonal antibody, or fragment thereof, of the present invention and CSF-1R such as the human CSF-1R polypeptide. | 2022-07-28 |
20220235140 | ANTIBODY WITH ENHANCED BINDING AFFINITY FOR ENDOTHELIN RECEPTOR TYPE A - The present invention relates to an antibody or an antigen-binding fragment thereof that has improved binding affinity for endothelin receptor type A. The present invention also relates to an antibody or an antigen-binding fragment thereof that has improved productivity. The antibody developed in the present invention is suitable for use in the treatment and diagnosis of diseases associated with endothelin receptor type A due to its remarkably improved binding affinity for the antigen and high productivity compared to conventional antibodies. | 2022-07-28 |
20220235141 | COMBINATION THERAPIES USING CDK INHIBITORS - This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof. | 2022-07-28 |
20220235142 | ANTI-CEACAM5 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF - Provided are a monoclonal antibody capable of specifically binding to human carcinoembryonic antigen cell adhesion molecule 5 (CEACAM5) and an antigen binding fragment thereof. Further provided are a preparation method for and use of said antibody and antigen binding fragment thereof. | 2022-07-28 |
20220235143 | HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF - Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression. | 2022-07-28 |
20220235144 | ANTI-SIRP-ALPHA ANTIBODIES - Described herein are anti-SIRPα antibodies, polynucleotides encoding anti-SIRPα antibodies, host cells containing such polynucleotides, methods of making and using such anti-SIRPα antibodies or polynucleotides, pharmaceutical compositions containing such anti-SIRPα antibodies or polynucleotides, as well as mixtures or bispecific antibodies comprising such anti-SIRPα antibodies or polynucleotides encoding such mixtures or bispecific antibodies. | 2022-07-28 |
20220235145 | PROXIMITY-BASED SORTASE-MEDIATED PROTEIN PURIFICATION AND LIGATION - The invention relates to proximity-based sortase-mediated protein purification and ligation. Specifically, the invention relates to techniques that links protein expression/purification with conjugation to therapeutic agents, imaging agents, or linkers. | 2022-07-28 |
20220235146 | ANTI-IgE ANTIBODIES - The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor). | 2022-07-28 |
20220235147 | METHOD FOR CONTROLLING AFFINITY OF ANTIBODY FOR ANTIGEN, ANTIBODY WHOSE AFFINITY FOR ANTIGEN HAS BEEN ALTERED, AND ITS PRODUCTION METHOD - Disclosed is a method for controlling affinity of an antibody for an antigen, comprising substituting at least 3 amino acid residues of framework region 3 (FR3) defined by the Chothia method with charged amino acid residues, in an antibody whose electrical characteristic of complementarity determining region (CDR) based on the amino acid sequence of the CDR is neutral or negatively charged. | 2022-07-28 |
20220235148 | ENGINEERING THE HINGE REGION TO DRIVE ANTIBODY DIMERIZATION - The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges as in many cases it is desired to specifically drive the specific pairing of multiple polypeptide chains that are present in solutions. In the case of the heavy chains, there are two main regions that form a dimer interface. One of them is the CH3 region, which has been widely exploited by inserting either charge-pair mutations (CPMs) to steer the dimer interface or inserting large bulky residues into cavities (Knob in Hole) to physically favor and disfavor the dimer formation. However, each of these strategies may not be applied to every molecule and therefore there is the need for more tools. Here, we describe the engineering of the Hinge region with a small number of mutations that are capable to alone successfully drive the heavy chain dimerization. | 2022-07-28 |
20220235149 | REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS AND FILMS MADE THEREFROM - Regioselectively substituted cellulose esters having a plurality of pivaloyl substituents and a plurality of aryl-acyl substituents are disclosed along with methods for making the same. Such cellulose esters may be suitable for use in films, such as +A optical films, and/or +C optical films. Optical films prepared employing such cellulose esters have a variety of commercial applications, such as, for example, as compensation films in liquid crystal displays and/or waveplates in creating circular polarized light used in 3-D technology. | 2022-07-28 |
20220235150 | SYSTEM AND METHOD FOR IMPROVING THE CORN WET MILL AND DRY MILL PROCESS - A novel dry mill process for producing pure starch, which can be used as a feed stock for bio tech processes. Corn feedstock is sent through a particle size reduction device, such as a hammer mill, to produce corn flour. The corn flour is screened into a small particle portion (which mainly contains “free” starch from the floury endosperm) and a larger particle portion (which mainly comprises the horny endosperm, germ pericarp and tip cap). The small particle potion is sent to a liquefication and a saccharification process to produce high Be corn syrup. A mud phase (mixture of oil, germ, and any light solid) is centrifuged. The light phase is sent to precoat drum filtration to produce clean corn syrup. Further, a novel wet mill process to produce starch and alcohol is disclosed. A three-section paddle screen can be used to separate starch from grit and fiber. | 2022-07-28 |
20220235151 | METHOD FOR PRODUCING PURIFIED CHLOROPRENE-BASED-POLYMER LATEX - Provided is a method for producing purified chloroprene-based-polymer latex which enables efficiently removing a residual volatile organic substance from chloroprene-based-polymer latex while suppressing foaming and the deposition of aggregates. The method for producing purified chloroprene-based-polymer latex of the present invention has at least the following steps (I) to (III): | 2022-07-28 |
20220235152 | METHOD FOR THE PRODUCTION OF SUPERABSORBERS - A process for producing superabsorbents, comprising polymerization of a monomer solution and thermal surface postcrosslinking, wherein the monomer solution comprises at least 0.75% by weight of a hydroxyphosphonic acid or salts thereof, calculated on the basis of the total amount of monomer used, and at least 0.09% by weight of aluminum cations, calculated on the basis of the total amount of polymer particles used, is added to the polymer particles before, during or after the thermal surface postcrosslinking. | 2022-07-28 |
20220235153 | PHOTOINITIATORS FOR LIGHT-CURABLE COMPOSITIONS - Compounds of formula (I) are photoinitiators or photosensitizers in a photopolymerizable composition: | 2022-07-28 |